CAR-T for newly diagnosed multiple myeloma without transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Injuries & trauma clinical trials.
This trial is testing a new immunotherapy treatment using CAR-T cells for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The treatment aims to target and destroy myeloma cells that have BCMA and GPRC5D proteins on their surface.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with multiple myeloma and have measurable signs of the disease in your blood or urine.
- You are unable or choose not to have a stem cell transplant (for example, because of age, health, or personal choice).
- Your myeloma cells have two specific proteins on their surface: BCMA and GPRC5D.
- Your liver and kidney function are working well enough (based on simple blood tests), and you haven't had CAR-T therapy or a BCMA-targeted treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy called BCMA CAR-T for people with multiple myeloma that is considered high-risk. It aims to see if this treatment can help patients who had a short response to initial therapy or have specific genetic changes in their cancer.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
Hear when a new Multiple Myeloma, Newly Diagnosed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.